These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8765434)

  • 1. Comparative pharmacokinetics of KRN8602, a new morpholino anthracycline, and adriamycin in tumor-bearing mice.
    Shinkai H; Takahashi H; Miyamoto K; Uchida T; Tokiwa T
    Cancer Chemother Pharmacol; 1996; 38(5):417-24. PubMed ID: 8765434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.
    Kubota T; Suto A; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
    Jpn J Cancer Res; 1990 Aug; 81(8):827-33. PubMed ID: 2144515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
    Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
    Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of adriamycin against a liver metastatic model by encapsulation in liposomes.
    Yachi K; Suzuki N; Tanaka N; Okada K; Mitsui I; Kawato Y; Komagata Y; Komiyama K; Kikuchi H
    Biopharm Drug Dispos; 1996 Nov; 17(8):699-715. PubMed ID: 8950048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines.
    Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
    Acta Med Okayama; 1992 Aug; 46(4):249-56. PubMed ID: 1442149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
    Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
    Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics and antitumor activity of MX2, a new morpholino anthracycline in brain tumor intracerebral transplanted in rats].
    Kiya K; Ogasawara H; Fujita H; Sugiyama K; Kurisu K; Kawamoto K; Uozumi T; Shinkai H
    Gan To Kagaku Ryoho; 1993 Apr; 20(5):631-5. PubMed ID: 8470921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
    Clarke K; Basser RL; Maher D; Morgan DJ; Cebon J; Fox RM; Hill JS; Alt C; Bartlett J; Geldard H; Kaye AH; Green MD
    J Clin Oncol; 1998 Jun; 16(6):2181-7. PubMed ID: 9626219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
    Hong WS; Jung HY; Yang SK; Kim HR; Min YI
    Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin.
    Formelli F; Carsana R; Pollini C
    Cancer Res; 1987 Oct; 47(20):5401-6. PubMed ID: 3652044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
    Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.
    Horichi N; Tapiero H; Sugimoto Y; Bungo M; Nishiyama M; Fourcade A; Lampidis TJ; Kasahara K; Sasaki Y; Takahashi T
    Cancer Res; 1990 Aug; 50(15):4698-701. PubMed ID: 2164445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of diameter of adriamycin polybutylcyanoacrylate nanoparticles on liver targeting].
    Shen LF; Wang X; Wang C; Zhao K; Liu XJ; Shen HJ
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):732-6, 741. PubMed ID: 17062941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
    Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
    Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and tissue distribution changes of adriamycin and adriamycinol after intravenous administration of adriamycin to uranyl nitrate-induced acute renal failure rats.
    Lee HJ; Paik WH; Lee MG
    Res Commun Mol Pathol Pharmacol; 1996 Feb; 91(2):195-204. PubMed ID: 8832911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.